2009 Fiscal Year Final Research Report

Individualized therapy for lung cancer based on LKB1 mutations.

Research Project

Project/Area Number	20790568
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Respiratory organ internal medicine
Research Institution	Tottori University
Principal Investigator	MATSUMOTO Shingo Tottori University, 医学部附属病院, 助教 (10392341)
Research Collaborator	NAKAMOTMO Masaki 鳥取大学, 医学部, 助教 HASHIMOTO Kiyoshi 鳥取大学, 医学部, 助教 TAKEDA Kennichi 鳥取大学, 医学部, 大学院生 NAKAZAKI Hirofumi 鳥取大学, 医学部, 大学院生
Project Period (FY)	2008 – 2009
Keywords	肺癌 / LKB1 / 抗癌剤感受性 / mTOR阻害剤 / PTEN
Research Abstract	Individualized drug therapies based on characteristics of cancer cell are needed to improve prognoses of lung cancer patients. It has been reported that targeted agents against activated molecules responsible for cancer developments and progressions were effective in several malignant tumors including lung cancers. Mutations of the LKB1 gene and the PTEN gene that activate mTOR signaling, resulting in cell proliferations, are frequently occurred in lung cancers. In the present study, we revealed that lung cancer cells with LKB1 or PTEN mutations were more sensitive to a mTOR inhibitor than those without the mutations. Thus, it is indicated that the new individualized drug therapy based on the gene mutations might be clinically useful for lung cancers.